<DOC>
	<DOCNO>NCT01423708</DOCNO>
	<brief_summary>Safety Efficacy Everolimus adult de novo liver transplant recipient .</brief_summary>
	<brief_title>Everolimus de Novo Liver Transplantation : Multicentre Randomized Study</brief_title>
	<detailed_description>This prospective study design evaluate feasibility effectiveness use Everolimus minimization possible suspension calcineurin inhibitor adult liver transplant patient . The study take account control group ( standard immunosuppression tacrolimus steroid ) induction anti-IL2 Antibodies .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Male female patient 18 70 year age , Patients undergo de novo liver transplantation cadaveric donor functional graft time randomization , Transplantation cadaveric donor whole split liver , Patients able communicate properly study investigator , understand respond need protocol give write consent Cold ischemia time &lt; 12 hour Physical laboratory abnormality mental illness within 2 week randomization , opinion investigator , may interfere participation study Women pregnant ( positive test hCG value &gt; 5mUI/ml ) breastfeed Women childbearing potential , following exception : ) woman menopause ( spontaneous amenorrhea least 12 month , spontaneous amenorrhea least 6 month FSH level &gt; 40 mIU/ml , surgical bilateral oophorectomy least 6 week baseline , without hysterectomy ) b ) woman use one reliable approve method contraception duration study three month follow discontinuation study treatment . Patients undergo transplantation multivisceral transplantation pancreatic islet , previously undergone organ transplantation tissue . Patients undergo combined liverkidney transplantation Patients undergo live donor liver transplantation Patients undergo ABOincompatible liver transplantation Patients undergo transplantation donor positive HBV surface antigen HIV History malignant disease site 3 year period prior , regardless whether evidence recurrence metastasis . ( Except nonmetastatic skin cancer basal cell squamous cell carcinoma skin , hepatocellular carcinoma ) Patients receive investigational drug within 4 week baseline currently enrol clinical trial Patients show hypersensitivity drug ( drug similar Everolimus Former macrolides ) class pharmaceutical excipients . Also , contraindication A history coagulopathy presence medical condition require longterm anticoagulant therapy transplantation ( The use lowdose ASA admissible ) Platelet count &lt; =40.000/mm3 WBC count &lt; 2000/mm3 hemoglobin &lt; =7g/dl time randomization Severe systemic infection High cholesterol level ( &gt; 350mg/dl ) severe hypertriglyceridemia ( &gt; 500mg/dl ) . Patients compensate hyperlipidemia eligible . Diagnosis pretransplant autoimmune liver disease ( PBC , sclerosing cholangitis ) Acute Liver Failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Liver Transplantation</keyword>
	<keyword>Graft Rejection</keyword>
	<keyword>Graft Survival</keyword>
	<keyword>Transplantation Immunology</keyword>
	<keyword>Anti-Rejection Therapy</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Organ Transplantation</keyword>
	<keyword>Host v Graft Reaction</keyword>
	<keyword>Gastroenterology</keyword>
	<keyword>Hepatology</keyword>
</DOC>